Compare Five Below Inc (FIVE) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Five Below Inc vs GeneDx Holdings Corp — how do they compare? Five Below Inc trades at $209.72 (market cap $11.55B), while GeneDx Holdings Corp trades at $67.6 (market cap $2.02B). The key difference: Five Below Inc is far larger — about 5.7× GeneDx Holdings Corp's market cap, and Five Below Inc is trading nearer its 52-week high, GeneDx Holdings Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Five Below Inc for 46 Days and GeneDx Holdings Corp for 19 Days on average.
| FIVE | WGS | |
|---|---|---|
Market Cap | $11.55B | $2.02B |
Volume | 1,120,554 | 734,640 |
Sector | Consumer Cyclical | Health |
52-Week High | $262.72 | $167.51 |
52-Week Low | $138.49 | $34.51 |
Typical Hold Time | 46 Days | 19 Days |
Enterprise Value | $12.40B | $2.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Five Below (FIVE) trades at $204.24, down 2.71% today but maintains strong analyst support with 60% buy ratings and a $298.44 consensus price target. The company shows robust revenue growth from $3.88B in 2025 to projected $5.3B in 2026, with earnings beating expectations in three consecutive quarters. Technical indicators show bearish momentum despite oversold RSI readings, with key support at $197.
FIVE presents a compelling growth story with expanding margins and strategic initiatives, though premium valuation (P/E 18.32) and execution risks warrant caution. The stock offers significant upside to analyst targets but faces near-term technical pressure and macroeconomic headwinds affecting consumer spending.
GeneDx (WGS) trades at $68.53, down 4.18% today amid bearish technical signals despite recent positive earnings surprises. The stock shows mixed fundamentals with strong revenue growth to $454M in 2026 but negative profitability metrics including -23.4% net margin. Recent developments include new genomic testing products and hospital partnerships, while analyst consensus remains strongly bullish with a $81 price target representing 18% upside potential.
The investment case balances strong analyst support and genomic testing market growth against persistent profitability challenges and negative cash flow trends. Key catalysts include Q3 2026 earnings due soon and continued execution on operational improvements, while risks center on margin recovery timeline and competitive pressures in the rapidly evolving genomics space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Five Below Inc
Five Below is a value-oriented retailer that operated 1,190 stores in the United States as of the end of fiscal 2021. Catering to teen and preteen consumers, stores feature a wide variety of merchandise, the vast majority of which is priced below $6. The assortment focuses on discretionary items in several categories, particularly leisure (such as sporting goods, toys, and electronics
Read more on FIVE →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
